{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:37:41Z","timestamp":1760834261258,"version":"build-2065373602"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,12,23]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The main objective was to evaluate the cost-effectiveness of various medical therapy combinations in managing chronic coronary syndrome (CCS) in Iran, based on real-world and patient-level data.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A cost-utility analysis employing a Markov model was conducted using data from a retrospective cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>The study was conducted in the healthcare setting of Iran, focusing on primary and secondary care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Patients with CCS were included in the study. Numbers entering and completing the study were reported, with clear definitions of selection, entry and exclusion criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>All combinations of recommended medical therapies for CCS were permitted. Ultimately, taking into account the sample size and study power, a comparison was made between the combination therapy of \u03b2-blockers (BB), long-acting nitroglycerin (LAN), aspirin (ASA) and statin versus the group receiving only BB, ASA and statin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Primary and secondary outcome measures<\/jats:title>\n                  <jats:p>The primary outcome measure was the incremental cost-effectiveness ratio, along with an initial evaluation of disability-adjusted life-years (DALYs) and costs related to the interventions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The BB\/LAN\/ASA\/statin combination was cost-saving and effective, averting 0.02 DALYs and saving $172 compared with BB\/ASA\/statin. This combination was cost-effective in over 97% of the probabilistic sensitivity analysis results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Incorporating LAN into the combination therapy of BB, ASA and statin is cost-effective in Iran. This finding provides evidence for policymakers on resource allocation in low-income countries.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-081953","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T21:55:15Z","timestamp":1736891715000},"page":"e081953","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-utility analysis of combination medical therapies in chronic coronary syndrome: a comparative study using real-world and patient-level data from Iran"],"prefix":"10.1136","volume":"15","author":[{"given":"Majid","family":"Davari","sequence":"first","affiliation":[{"name":"Pharmacoeconomics and Pharmaceutical Administration, Tehran University of Medical Sciences School of Pharmacy, Tehran, Iran (the Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7912-7546","authenticated-orcid":false,"given":"Behzad","family":"Fatemi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Management and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-0513","authenticated-orcid":false,"given":"Parham","family":"Sadeghipour","sequence":"additional","affiliation":[{"name":"Vascular Disease and Thrombosis Research Center, Rajaie Cardiovascular Institute, Iran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Kebriaeezadeh","sequence":"additional","affiliation":[{"name":"Pharmacoeconomics and Pharmaceutical Administration, Tehran University of Medical Sciences School of Pharmacy, Tehran, Iran (the Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Maracy","sequence":"additional","affiliation":[{"name":"Epidemiology and Biostatistics, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Soleymani","sequence":"additional","affiliation":[{"name":"Pharmacoeconomics and Pharmaceutical Administration, Tehran University of Medical Sciences School of Pharmacy, Tehran, Iran (the Islamic Republic of)"},{"name":"Pharmaceutical Management & Economic Research Center, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6067-040X","authenticated-orcid":false,"given":"Nasim","family":"Naderi","sequence":"additional","affiliation":[{"name":"Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saman","family":"Zartab","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (the Islamic Republic of)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"2025101811383744000_15.1.e081953.1","doi-asserted-by":"publisher","DOI":"10.5830\/CVJA-2015-036"},{"key":"2025101811383744000_15.1.e081953.2","unstructured":"World Health Organization . Tackling NCDs:\u2019best buys\u2019 and other recommended interventions for the prevention and control of noncommunicable diseases. World Health Organization; 2017."},{"key":"2025101811383744000_15.1.e081953.3","unstructured":"World Health Organization . Noncommunicable diseases country profiles 2018. 2018."},{"key":"2025101811383744000_15.1.e081953.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"2025101811383744000_15.1.e081953.5","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(13)70089-5"},{"key":"2025101811383744000_15.1.e081953.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.561647"},{"key":"2025101811383744000_15.1.e081953.7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1586\/14737167.2014.957681","article-title":"The cost-effectiveness of strategies in coronary artery disease","volume":"14","author":"Scudeler","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025101811383744000_15.1.e081953.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.798462"},{"key":"2025101811383744000_15.1.e081953.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.084442"},{"key":"2025101811383744000_15.1.e081953.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281718"},{"key":"2025101811383744000_15.1.e081953.11","first-page":"e435","article-title":"Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association","volume":"131","author":"Rosendorff","year":"2015","journal-title":"Am Coll Cardiol Am Soc Hypertens Circ"},{"key":"2025101811383744000_15.1.e081953.12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.29252\/jarums.18.3.341","article-title":"The Economic Burden of Coronary Heart Disease in Iran: A Bottom-up Approach in 2014","volume":"18","author":"Raghfar","year":"2018","journal-title":"J Ardabil Univ Med Sci"},{"key":"2025101811383744000_15.1.e081953.13","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1093\/eurheartj\/ehz425","article-title":"Corrigendum to: 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2025101811383744000_15.1.e081953.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2014.05.013"},{"key":"2025101811383744000_15.1.e081953.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.07.017"},{"key":"2025101811383744000_15.1.e081953.16","doi-asserted-by":"crossref","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022","volume":"38","author":"Husereau","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"key":"2025101811383744000_15.1.e081953.17","doi-asserted-by":"crossref","unstructured":"Davari M , Sorato MM , Fatemi B , et al . Factors Associated with Re-hospitalization and Status of Risk Factors among Patients with Stable Coronary Artery Disease Referring for Medical Therapy: An Unmatched Cohort Study. Iran Red Crescent Med J 2022;24. doi:10.32592\/ircmj.2022.24.1.1257","DOI":"10.32592\/ircmj.2022.24.1.1257"},{"key":"2025101811383744000_15.1.e081953.18","first-page":"1","article-title":"Medical therapy versus percutaneous coronary intervention or coronary artery bypass graft in stable coronary artery disease; a systematic review and meta-analysis of randomized clinical trials","volume":"18","author":"Davari","year":"2022","journal-title":"ARYA Atheroscler J"},{"key":"2025101811383744000_15.1.e081953.19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009113","article-title":"Utility and quality-adjusted life-years in coronary artery disease: Five-year follow-up of the MASS II trial","volume":"96","author":"Brand\u00e3o","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2025101811383744000_15.1.e081953.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13690-017-0174-z","article-title":"Mapping EQ-5D utilities to GBD 2010 and GBD 2013 disability weights: results of two pilot studies in Belgium","volume":"75","author":"Maertens de Noordhout","year":"2017","journal-title":"Arch Public Health"},{"key":"2025101811383744000_15.1.e081953.21","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(15)00069-8"},{"key":"2025101811383744000_15.1.e081953.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110717"},{"key":"2025101811383744000_15.1.e081953.23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/eurheartj\/ehaa001","article-title":"Chronic coronary syndromes: expanding the spectrum and natural history of ischaemic heart disease","volume":"41","author":"L\u00fcscher","year":"2020","journal-title":"Eur Heart J"},{"key":"2025101811383744000_15.1.e081953.24","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17696997"},{"key":"2025101811383744000_15.1.e081953.25","article-title":"Chronic Coronary Syndrome Med Ther or Myocard Revasc?","volume":"36","author":"Rocha","year":"2022","journal-title":"Int J Cardiovasc Sci"},{"key":"2025101811383744000_15.1.e081953.26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019114","article-title":"Death and Myocardial Infarction Following Initial Revascularization Versus Optimal Medical Therapy in Chronic Coronary Syndromes With Myocardial Ischemia: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials","volume":"10","author":"Soares","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025101811383744000_15.1.e081953.27","article-title":"Medical therapy versus percutaneous coronary intervention in ischemic heart disease: A cost-effectiveness analysis","volume":"34","author":"Rezapour","year":"2020","journal-title":"Med J Islam Repub Iran"},{"key":"2025101811383744000_15.1.e081953.28","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.15829\/1560-4071-2020-3819","article-title":"Rationale for revascularization to improve prognosis in stable coronary artery disease: the data from ISCHEMIA trial","volume":"25","author":"Bershtein","year":"2020","journal-title":"Russ J Cardiol"},{"key":"2025101811383744000_15.1.e081953.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003059"},{"key":"2025101811383744000_15.1.e081953.30","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1253\/circj.CJ-19-0148","article-title":"Cost-Effectiveness of Percutaneous Coronary Intervention Compared With Medical Therapy for Ischemic Heart Disease in Japan","volume":"83","author":"Kodera","year":"2019","journal-title":"Circ J"},{"key":"2025101811383744000_15.1.e081953.31","doi-asserted-by":"publisher","DOI":"10.4158\/EP171764.APPGL"},{"key":"2025101811383744000_15.1.e081953.32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2174\/1573403X13666170426104611","article-title":"The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature","volume":"13","author":"Diamantis","year":"2017","journal-title":"Curr Cardiol Rev"},{"key":"2025101811383744000_15.1.e081953.33","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8295054","article-title":"Burden of Coronary Artery Disease and Peripheral Artery Disease: A Literature Review","volume":"2019","author":"Bauersachs","year":"2019","journal-title":"Cardiovasc Ther"},{"key":"2025101811383744000_15.1.e081953.34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arcmed.2019.04.001","article-title":"Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study","volume":"50","author":"Castellano","year":"2019","journal-title":"Arch Med Res"},{"key":"2025101811383744000_15.1.e081953.35","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1177\/2047487317695628","article-title":"The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis","volume":"24","author":"Du","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2025101811383744000_15.1.e081953.36","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamacardio.2017.2249","article-title":"Optimal Medical Therapy for Known Coronary Artery Disease: A Review","volume":"2","author":"Gibbons","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025101811383744000_15.1.e081953.37","first-page":"e21","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Members","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-081953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:38:45Z","timestamp":1760812725000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-081953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,14]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjopen-2023-081953"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-081953","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}